Desfoxine Use In Pregnancy & Lactation

Pregnancy: The safety of Desvenlafaxine in human pregnancy has not been established. Desvenlafaxine must only be administered to pregnant woman if the expected benefits outweigh the possible risks. If Desvenlafaxine is used until, or shortly before birth, discontinuation effects in the newborn should be considered.
Some neonate exposed to Serotonin Norepinephrine reuptake inhibitors (SNRIs) or Selective serotonin reuptake inhibitors (SSRIs) late in the third trimester of pregnancy have developed complications that have sometimes been severe and required prolonged hospitalization, respiratory support, enteral nutrition, and other forms of supportive care in special-care nurseries. Such complications may arise immediately upon delivery.
Lactation: Desvenlafaxine is excreted into human milk. Because of the potential for serious adverse effects in nursing infants from Desvenlafaxine, discontinue nursing or the drug, considering the importance of the drug to the woman. Desvenlafaxine should only be administered to nursing woman if the expected benefits outweigh any possible risk.